Why does everyone think a reverse split to uplist is a bad thing? Trading on the NASDAQ would open up the stock to be bought by many more investment entities.
Jason says AMBS is a "BUY" with a .20 price target.
Get in at a nickle.
Bio-tech analyst Jason Napadano says it's worth .20 currently.
Read the recent Yahoo news.
The company's drug, MANF, already has one orphan indication for Retinitis Pigmentosa. It also has another one to be announced soon. Possible treatment for Alzheimer's and Parkinson's.
Research Amarantus Bioscience.
Dr. Joseph Rubinfeld, one of the co-founders of Amgen, is on the comapny's advisory board.
AMBS offers substantially more upside than AMRN. AMBS offers 500% upside within 12 months. AMRN offers 50% downside in the same period.
Guess I was a bit too optimistic. Wonder who are the ones who gave me the thumbs down.
Buy AMBS under six cents and hold for two years.